ClinicalTrials.gg
RecruitingNCT06066983Updated Nov 4, 2026

DINO RCT - Treating Anxiety in Children With Autism

An interventional study of DINOSAUR and Psychoeducation in Autism Spectrum Disorder and Anxiety Disorders, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, Inc.. Recruiting at 1 site in United States. Open to participants aged 4 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
4 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Autism Spectrum Disorder by Hugo W. Moser Research Institute at Kennedy Krieger, Inc. — 1 open to participants now, 2 under way, none of them phase 3. Autism Spectrum Disorder · Hugo W. Moser Research Institute at Kennedy Krieger, Inc..

Planned enrollment
5th of 13
70 · median 61
Started
2024
the only one that year
No phase
12 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Autism Spectrum Disorder by Hugo W. Moser Research Institute at Kennedy Krieger, Inc., this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 12 with no phase, and was the 15th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

1 of the 15 studies in Autism Spectrum Disorder by Hugo W. Moser Research Institute at Kennedy Krieger, Inc. is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 4 Years to 6 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Autism Spectrum Disorder by Hugo W. Moser Research Institute at Kennedy Krieger, Inc., or all of them as a file.
02

Study summary

Anxiety is prevalent in young children, under 7 years of age, with autism. Yet, few studies have examined anxiety interventions for this age range, and only one anxiety treatment study has included young children with cognitive and language delays. Anxiety treatment models utilizing cognitive-behavioral therapy (CBT), adapted for children with autism, are empirically supported in school-age autistic children. Further, preliminary evidence suggests CBT approaches may reduce intolerance of uncertainty (IU), a mechanistic construct that may contribute to the maintenance of anxiety in autistic children. This study seeks to address the existing gap in anxiety treatment by examining the feasibility and preliminary efficacy of a novel, telehealth CBT intervention, DINO Strategies for Anxiety and intolerance of Uncertainty Reduction (DINOSAUR), which targets both anxiety and IU in young autistic children.

Read the detailed description

The purpose of this study is to examine the feasibility and preliminary efficacy of a new treatment that targets both anxiety and IU, i.e., DINOSAUR, in young autistic children with varying cognitive and language levels. To accomplish this goal, we will investigate if DINOSAUR is a feasible intervention for families of young autistic children. We will also investigate if DINOSAUR is superior to an active control condition in reducing anxiety and IU. A third, exploratory goal is to understand how children's language and cognitive level affect their response to anxiety treatment. Seventy children, 4-6 years of age with autism and clinically significant anxiety, and their parents will be randomly assigned to receive either DINOSAUR or the active control (35 in each group) over 14 weeks via telehealth. Within each condition, children will be stratified based on cognitive level. Anxiety and IU will be assessed following treatment and at 4-month follow-up.

03

Conditions studied

  • Autism Spectrum Disorder
  • Anxiety Disorders
04

Who can participate

Ages eligible
4 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 4 years 0 months to 6 years 11 months
  • ASD diagnosis based on clinical impressions and results of the Autism Diagnostic Observation Schedule-2 (ADOS-2)
  • CBCL Anxiety Problems T-score > 65
  • SB-5 ABIQ > 60
  • Receptive and expressive language age equivalent > 36 months based on Test of Early Language Development, Fourth Edition (TELD-4)
  • Parent (or other caregiver) available and willing to attend 14-week intervention
  • Absence of identifiable neurological (e.g., epilepsy), genetic (e.g., Down syndrome, fragile X, tuberous sclerosis, neurofibromatosis) or severe sensory-motor (e.g., severe vision impairment) conditions
  • Able to walk independently (a requirement for ADOS-2)

Exclusion criteria

Exclusion Criteria:

  • Primary language other than English
  • Child is in foster care
  • Child displays severe behavior challenges that prevent participation in treatment groups (i.e., severe tantrums, aggression, or self-injury)
  • Participating parent experiencing active symptoms of substance abuse or severe mental illness (i.e., schizophrenia, bipolar disorder)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Treatment

    Parent-child dyads will receive DINOSAUR, a group-based cognitive-behavioral therapy (CBT) intervention, adapted for young children and delivered via telehealth. This 14 week intervention teaches parents and children strategies to reduce anxiety and intolerance of uncertainty, an underlying construct of anxiety.

    Behavioral: DINOSAUR

  • Active comparator
    Active Control

    Parents in the active control condition will participate in three psychoeducational groups focused on presenting information regarding anxiety prevalence, differentiating anxiety from autism, and anxiety triggers. These groups will be delivered via telehealth across a 14-week period.

    Other: Psychoeducation

Interventions

  • BehavioralDINOSAUR

    This intervention aims to treat intolerance of uncertainty and anxiety in young autistic children.

  • OtherPsychoeducation

    This intervention provides psychoeducation regarding anxiety and autism.

06

What researchers measure

Primary outcomes

  1. Change in child anxiety diagnostic status on Anxiety Disorders Interview Schedule, Autism Spectrum Disorder Addendum (ADIS-ASA)

    The Anxiety Disorders Interview Schedule (ADIS) is a semi-structured parent interview assessing the severity of anxiety disorders and its presentation in individuals with autism.

    Time frame: Before and after 14-week treatment (baseline to post-treatment)

Secondary outcomes

  1. Change in anxiety severity on Child Behavior Checklist

    An established 99-item parent and teacher report of broad psychopathology; T scores range from 20 to 100; Syndrome scales: T-scores over 65 indicate clinically significant symptoms.

    Time frame: Before and after 14-week treatment (baseline to post-treatment) and at 4 month follow-up

  2. Change in child's intolerance of uncertainty on Response to Uncertainty and Low Environmental Stability Scale

    Parent and teacher report scale measuring response to uncertainty and low environmental structure; scores range from 1 to 5; higher scores indicate higher intolerance of uncertainty.

    Time frame: Before and after 14-week treatment (baseline to post-treatment) and at 4 month follow-up

  3. Change on parental accommodating behaviors on Family Accommodation Scale following 14-week active control and 14-week intervention.

    Assesses parental accommodating behaviors; scores range from 0 to 36; higher scores indicate higher parental accommodation.

    Time frame: Before and after 14-week treatment (baseline to post-treatment) and at 4 month follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Keefer A, Vasa RA. DINOSAUR: an integrated cognitive-behavioral treatment for anxiety in young children with ASD. J Neurodev Disord. 2021 Oct 11;13(1):46. doi: 10.1186/s11689-021-09396-9. PubMed 34635048 ↗
  • Vasa RA, Kerns CM, Singh V, McDonald R, Jang YS, Keefer A. Anxiety in autistic preschool children: Phenomenology and a network analysis of correlates. Autism Res. 2023 Aug;16(8):1561-1572. doi: 10.1002/aur.2968. Epub 2023 Jun 23. PubMed 37350221 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 35 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 4, 2023
StartActual
Jan 2, 2024
Primary completionEst.
Dec 31, 2026was Oct 2026
CompletionEst.
Dec 31, 2026was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 15, 2026→Dec 31, 2026
Nov 4, 2026
Study completion
Oct 15, 2026→Dec 31, 2026
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Oct 15, 2026→Dec 31, 2026
    Study completion Oct 15, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06066983
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Responsible party
Amy Keefer (Principal Investigator, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.) — Principal investigator
First posted
Oct 4, 2023
Start date
Jan 2, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 4, 2026

Study contacts

Belina Onomake
Contact
OnomakeB@kennedykrieger.org
667-205-4036
Amy Keefer, PhD
Contact
keefer@kennedykrieger.org
443-923-7603

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion